Leerink analyst Whit Mayo lowered the firm’s price target on Ardent Health (ARDT) to $16 from $23 and keeps an Outperform rating on the shares following Q3 results. The firm believes the equity reaction seems overly harsh compared to the guide down. However, Leerink can see a probable scenario that there is entirely no growth next year, the firm told investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARDT:
- Ardent Health price target lowered to $16 from $21 at RBC Capital
- Ardent Health price target lowered to $17 from $19 at Loop Capital
- Ardent Health price target lowered to $13 from $21 at Truist
- Ardent Health price target lowered to $12 from $19 at Goldman Sachs
- Ardent Health price target lowered to $17 from $21 at Stephens